CSPC Innovation Suspends Trading Amid Proposed Acquisition and Fundraising

Reuters
2025.11.02 22:13
portai
I'm PortAI, I can summarize articles.

CSPC Pharmaceutical Group Ltd. has suspended trading of CSPC Innovation amid a proposed acquisition and fundraising efforts. CSPC NBP Pharmaceutical Co., Ltd., a wholly-owned subsidiary, is the largest shareholder of CSPC Innovation. This news is generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

CSPC Pharmaceutical Group Ltd. has several subsidiaries, including CSPC Innovation Pharmaceutical Co., Ltd. and CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. CSPC NBP Pharmaceutical Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group, is the largest shareholder of CSPC Innovation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer